Corrigendum to “Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer” [Eur Urol 2023;83:313–17] (European Urology (2023) 83(4) (313–317), (S0302283822025386), (10.1016/j.eururo.2022.07.023))

Journal article (2023)

Authors

A. Gil Jimenez Netherlands Cancer Institute, Oncode Institute
Jeroen van Dorp Netherlands Cancer Institute
Alberto Contreras-Sanz University of British Columbia
Kristan van der Vos Netherlands Cancer Institute
Daniel J. Vis Netherlands Cancer Institute
Linde Braaf Netherlands Cancer Institute
Annegien Broeks Netherlands Cancer Institute
Antonio Alcaraz Universitat Politecnica de Catalunya
L.F.A. Wessels Netherlands Cancer Institute, Pattern Recognition and Bioinformatics - EEMCS , Oncode Institute
More Authors More Authors External organisation
Research Group
Pattern Recognition and Bioinformatics (EEMCS) (TU Delft)
Copyright: © 2023 A. Gil Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, Kristan van der Vos, Daniel J. Vis, Linde Braaf, Annegien Broeks, Antonio Alcaraz, L.F.A. Wessels, More Authors
DOI
help_outline
https://doi.org/10.1016/j.eururo.2023.03.002
More Info
expand_more

Published Date

2023

Language

English

Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Faculty

Electrical Engineering, Mathematics and Computer Science

Department

Intelligent Systems

Research Group

Pattern Recognition and Bioinformatics

Abstract

The authors regret that the following statement regarding author contributions was missed: Kristan van der Vos is currently a Scientific Editor for Cell Reports Medicine, which is published by Elsevier. Dr van der Vos was not involved in the peer-review process or editorial discussions about this manuscript. The authors would like to apologise for any inconvenience caused.